GenMark Diagnostics (GNMK) Tops Q2 EPS by 2c, Raises FY Revenue Guidance

GenMark Diagnostics (NASDAQ: GNMK) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $6.55 million versus the consensus estimate of $4.79 million.

GenMark Diagnostics sees FY2014 revenue of $28 million, versus prior guidance of $25 million and the consensus of $25.5 million.

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Rivian reports Q3 2026 production of 19,751 vehicles
• Investing.com’s stocks of the week